High cytoplasm HABP1 expression as a predictor of poor survival and late tumor stage in pancreatic ductal adenocarcinoma patients
High cytoplasm HABP1 expression as a predictor of poor survival and late tumor stage in pancreatic ductal adenocarcinoma patients
复制标题
细胞质 HABP1 高表达是胰腺导管腺癌患者生存不良和晚期肿瘤分期的预测因子
DOI：
10.1016/j.ejso.2018.09.020
复制
发表时间：
2019-02-01
期刊：
影响因子：
3.8
通讯作者：
Fu, De-Liang
中科院分区：
文献类型：
--
作者：
Xie, Zhi-Bo;Yao, Lie;Fu, De-Liang
背景资料：已证实在不同的恶性肿瘤中存在HABP 1过表达，并发现其与肿瘤的发生和进展密切相关。为探讨HABP 1在胰腺导管腺癌（PDAC）中的作用，采用免疫组化方法检测89例PDAC组织中HABP 1的表达。PDAC组织中HABP 1在胞核和胞浆均呈高表达。总生存率分析显示，HABP 1表达低和高光密度值的患者的平均生存率相似（P = 0.312）。核HABP 1低、中、高表达组间也有相似的结果（P = 0.275）。然而，HABP 1过表达的患者的平均生存率明显较差（P < 0.001）。HABP 1在PDAC中的高表达与肿瘤的晚期分期、动脉受累、淋巴结转移及糖链抗原19-9水平密切相关。HABP 1可作为一个有前途的生物标志物，以确定PDAC患者的高度恶性临床行为的子集。(C)2018 Elsevier Ltd，BASO类似于癌症外科协会和欧洲外科肿瘤学会。All rights reserved.
Background: Hyaluronan-binding protein 1 (HABP1) overexpression has been confirmed in different malignancies and found to be strongly associated with tumor development and progression. The aim of the present study was to explore the impact of HABP1 in pancreatic ductal adenocarcinoma (PDAC) patients.Method: HABP1 expression was evaluated in 89 PDAC specimens.Results: The expression of HABP1 was significantly higher in tumor tissues than that in adjacent normal tissues. High nucleus HABP1 expression and high cytoplasm HABP1 expression were both detected in PDAC tissues. Overall survival analysis by optical density showed that the mean survival was similar between patients with low and high optical density values of HABP1 expression (P = 0.312). The similar result was also found between patients with low-moderate or high nucleus HABP1 expression (P = 0.275). However, the mean survival was significantly poorer in patients with cytoplasm HABP1 overexpression (P < 0.001). High cytoplasm HABP1 expression was strongly correlated with late tumor stages, arterial involvement, lymph node metastasis and carbohydrate antigen 19-9 levels.Conclusion: High cytoplasm HABP1 expression may prove to be a predictor of poor survival and late tumor stage in PDAC patients. HABP1 could serve as a promising biomarker to identify subsets of PDAC patients with high malignant clinical behavior. (C) 2018 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.